AUROBINDO PHARMA Surges by 5%; BSE HEALTHCARE Index Up 2.8%

Wed, 15 Apr 09:28 AM

AUROBINDO PHARMA share price has zoomed 5% and is presently trading at Rs 532.

Meanwhile, the BSE HEALTHCARE Index is at 15,194 (up 2.8%).

Among the top Gainers in the BSE HEALTHCARE Index today are AUROBINDO PHARMA (up 5.1%) and GSK PHARMA (up 5.7%).

IPCA LABS (down 1.3%) is among the top loser today.

Over the last one year, AUROBINDO PHARMA has moved down from Rs 778 to Rs 532, registering a loss of Rs 246 (down 32.0%).

On the other hand, the BSE HEALTHCARE has moved up from 14,506 to 15,194, registering a gain of 688 points (up 4.7%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were ABBOTT INDIA (up 122.4%), IPCA LABS (up 62.2%) and ALKEM LABORATORIES (up 56.0%).

REVEALED: How to Potentially Make Up to Tens of Thousands of Rupees Within a Few Hours...

What About the Benchmark Indices?

The BSE Sensex is at 31,400 (up 1.9%).

The top gainers among the BSE Sensex stocks today are ICICI BANK (up 4.0%), AXIS BANK (up 3.8%) and INDUSIND BANK (up 3.8%). Other gainers include SUN PHARMA (up 3.7%) and TECH MAHINDRA (up 3.6%). The most traded stocks in the BSE Sensex are SBI and AXIS BANK.

In the meantime, NSE Nifty is at 9,200 (up 1.7%). The top gainers in the NSE Nifty include HINDALCO (up 8.5%), UPL (up 7.7%) and SHREE CEMENT (up 3.9%). Other gainers include L&T (up 3.6%) and SUN PHARMA (up 3.5%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved down from 38,906 to 31,400, registering a loss of 7,506 points (down 19.62%).

AUROBINDO PHARMA Financial Update...

AUROBINDO PHARMA net profit down at Rs 7 billion for the quarter ended December 2019, compared to a loss of Rs 7 billion a year ago. Net Sales rose 10.1% to Rs 58.0 billion during the period as against Rs 52.7 billion in October-December 2018.

For the year ended March 2019, AUROBINDO PHARMA reported 1.2% increase in net profit to Rs 24.5 billion compared to net profit of Rs 24.2 billion during FY18.

Revenue of the company grew 18.6% to Rs 196 billion during FY19.

The current Price to earnings ratio of AUROBINDO PHARMA, based on rolling 12 month earnings, stands at 12.1x.

Indian Share Market Update: Top Gainers and Losers

What else is happening in the markets today? Dig in...